Dataset from A Multicentre, 12 Week Double Blind Placebo Controlled Randomized Study Of Etanercept On A Background Nsaid In The Treatment Of Adult Subjects With Non Radiographic Axial Spondyloarthritis With A 92 Week Open Label Extension

This is a two part study. During period one there will be a comparison of Etanercept (ETN)
against a placebo with both arms maintaining the background anti inflammatory drug prescribed
by their Physician. The hypothesis is that Etanercept will be superior to the placebo arm as
determined by the proportion of subjects achieving Assessments in Ankylosing Spondylitis
(ASAS)40 improvement at 12 weeks. This will be followed by 92 weeks extension where everyone
in the trial receives Etanercept (ETN) and a background non steroidal anti inflammatory
drug(NSAID).